Fees for Redeeming Priority Review Vouchers Fall to All-Time Low in FY2020

The US Food and Drug Administration (FDA) on Friday announced the fees for using a priority review voucher (PRV) to speed the review of a new drug, biologic or medical countermeasure for vouchers redeemed in FY2020.